Nutex Health Croissance future
Future contrôle des critères 1/6
Nutex Health devrait augmenter ses bénéfices et ses revenus de 6.7% et de 8.1% par an respectivement, tandis que le BPA devrait croître de croître de 0.7% par an.
Informations clés
6.7%
Taux de croissance des bénéfices
0.71%
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 17.4% |
| Taux de croissance des recettes | 8.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 04 Sep 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Sep 08
NUTX: Arbitration Model And Micro Hospitals Will Drive Future Upside
Nutex Health’s updated analyst price target has moved from $290 to $325, with analysts pointing to the company’s micro-hospital footprint, arbitration-driven model, and capital-light expansion approach as key support for the higher fair value estimate. Analyst Commentary Recent research on Nutex Health focuses on how its micro-hospital network, arbitration-driven revenue model, and capital-light expansion plans feed into the updated valuation views.
Mise à jour du récit • Aug 25
NUTX: Arbitration Reset And Capital-Light Expansion Will Shape Future Upside
Analysts have raised their Nutex Health fair value estimate to $200 from $175, reflecting updated assumptions that factor in recent price target increases on the stock, a shift in projected revenue growth and profitability, and changes in expected future P/E levels. Analyst Commentary on Nutex Health Recent Street research on Nutex Health points to a mix of optimism around the company’s business model and questions about the quality and sustainability of some profit drivers.Seeking Alpha • Aug 12
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)
Summary Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods. With a 6.6x GAAP TTM PE, upside catalysts include the No Surprises Enforcement Act and $356 million in accounts receivable potentially converting to cash. Read the full article on Seeking AlphaMise à jour du récit • Aug 10
NUTX: Arbitration Model And Margin Gains Will Support Future Upside
Nutex Health's analyst price target has shifted from $235.50 to $266.40. Analysts point to fresh coverage highlighting its micro hospital model, arbitration driven reimbursement approach, and capital light expansion plans as key factors in their updated views.Mise à jour du récit • Jun 22
NUTX: Low EV EBITDA Multiple And Buyback Activity Will Support Future Upside
Analysts nudged their Nutex Health price target to $235, pointing to what they view as a low ~3x EV/EBITDA multiple, limited existing coverage, and ongoing investor confusion around the No Surprises Act as key factors behind their valuation work. What’s in the News for Nutex Health Nutex Health reported completing a share repurchase tranche between March 5, 2026 and March 31, 2026, buying 21,086 shares, or 0.3% of outstanding shares, for a total of US$3.02 million under the buyback announced on March 5, 2026.Mise à jour du récit • Jun 04
NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential
Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.Mise à jour du récit • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Mise à jour du récit • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Mise à jour du récit • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).Mise à jour du récit • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Mise à jour du récit • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Mise à jour du récit • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Mise à jour du récit • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Mise à jour du récit • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Mise à jour du récit • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Mise à jour du récit • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Mise à jour du récit • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Nouveau récit • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Article d’analyse • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Article d’analyse • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Article d’analyse • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 1,014 | 206 | N/A | N/A | 1 |
| 12/31/2027 | 964 | 208 | N/A | N/A | 5 |
| 12/31/2026 | 872 | 198 | N/A | N/A | 5 |
| 6/30/2026 | 847 | 180 | 272 | 280 | N/A |
| 3/31/2026 | 880 | 96 | 265 | 273 | N/A |
| 12/31/2025 | 875 | 71 | 241 | 248 | N/A |
| 9/30/2025 | 981 | 121 | 174 | 178 | N/A |
| 6/30/2025 | 792 | 56 | 81 | 85 | N/A |
| 3/31/2025 | 624 | 74 | 69 | 71 | N/A |
| 12/31/2024 | 480 | 52 | 21 | 23 | N/A |
| 9/30/2024 | 292 | -41 | 20 | 21 | N/A |
| 6/30/2024 | 276 | -38 | 13 | 17 | N/A |
| 3/31/2024 | 259 | -41 | -3 | 3 | N/A |
| 12/31/2023 | 248 | -46 | -8 | 1 | N/A |
| 9/30/2023 | 232 | -29 | 5 | 8 | N/A |
| 6/30/2023 | 197 | -436 | -7 | -2 | N/A |
| 3/31/2023 | 196 | -451 | 6 | 16 | N/A |
| 12/31/2022 | 219 | -425 | 36 | 51 | N/A |
| 9/30/2022 | 229 | -396 | 58 | 93 | N/A |
| 6/30/2022 | 319 | 70 | 92 | 124 | N/A |
| 3/31/2022 | 336 | 122 | 123 | 158 | N/A |
| 12/31/2021 | 332 | 133 | 137 | 173 | N/A |
| 9/30/2021 | 374 | 159 | 94 | 160 | N/A |
| 12/31/2020 | 274 | 106 | 25 | 87 | N/A |
| 12/31/2019 | 97 | 21 | N/A | 12 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de NUTX ( 6.7% par an) est supérieure au taux d'épargne ( 3.7% ).
Bénéfices vs marché: Les bénéfices de NUTX ( 6.7% par an) devraient croître plus lentement que le marché US ( 17.1% par an).
Croissance élevée des bénéfices: Les bénéfices de NUTX devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de NUTX ( 8.1% par an) devrait croître plus lentement que le marché de US ( 13.3% par an).
Croissance élevée des revenus: Le chiffre d'affaires de NUTX ( 8.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de NUTX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/15 18:37 |
| Cours de l'action en fin de journée | 2026/09/15 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Nutex Health Inc. est couverte par 7 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |
| Eugene Mannheimer | Freedom Capital Markets |